Rankings
▼
Calendar
EBS Q2 2016 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$430M
Q2 2016 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$91M
Gross Profit
$34M
37.1% margin
Operating Income
-$2M
-2.2% margin
Net Income
-$11M
-12.0% margin
EPS (Diluted)
$-0.27
QoQ Revenue Growth
-11.4%
Cash Flow
Operating Cash Flow
-$2M
Free Cash Flow
-$23M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$384M
Stockholders' Equity
$673M
Cash & Equivalents
$333M
← FY 2016
All Quarters
Q3 2016 →